The intravenous immunoglobulin market size is expected to grow by 7.50% and is expected to reach USD 20.96 Billion during the forecast period.
The Intravenous Immunoglobulin (IVIG) market is witnessing significant growth as a crucial component in the treatment of various autoimmune and immunodeficiency disorders. Intravenous Immunoglobulin therapy, commonly known as IVIG treatment, involves the administration of immunoglobulin intravenously to enhance the body's immune response.
IVIG is derived from pooled human plasma and contains antibodies that can help modulate the immune system. It is utilized in the management of conditions such as primary immunodeficiency disorders, autoimmune diseases, and neurological disorders. The global Intravenous Immunoglobulin market is driven by the increasing prevalence of immune system-related disorders and the growing awareness about the therapeutic benefits of IVIG treatment.
The key factor contributing to the market's growth is the rising incidence of autoimmune diseases worldwide. Conditions like rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are on the rise, necessitating advanced therapeutic interventions like IVIG treatment. Additionally, the expanding geriatric population, which is more susceptible to immunodeficiency disorders, further propels the demand for Intravenous Immunoglobulin.
The market is characterized by the presence of major players investing in research and development to introduce novel IVIG products with enhanced efficacy and safety profiles. The increasing adoption of IVIG treatment in neurological disorders, such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, is also contributing to market growth.
The market's growth is fueled by advancements in healthcare infrastructure, growing awareness regarding immunoglobulin therapy benefits, and favorable reimbursement policies. Additionally, the escalating research and development activities aimed at expanding the therapeutic applications of IVIG further contribute to market expansion.
With the advent of novel technologies and formulations, IVIG manufacturers are focused on enhancing product efficacy, safety, and patient convenience. The introduction of subcutaneous immunoglobulin (SCIG) therapies provides patients with alternative administration options, driving market penetration.
Moreover, strategic collaborations, mergers, and acquisitions among pharmaceutical companies are shaping the competitive landscape of the IVIG market. These alliances aim to leverage combined expertise, expand product portfolios, and strengthen market presence, ensuring sustained growth and market dominance.
Major Key Players:
Some of the Intravenous Immunoglobulin Companies are ABEONA THERAPEUTICS (US), Baxter (US), BDI Pharma (US), Biotest AG.(Germany),, China Biologic Products, Inc. (China), CSL Behring (US), Grifols Inc. (Spain), Kedrion S.p.A (us), Octapharma (Switzerland), Shire (Republic of Ireland), AND others.
Segment Analysis
Intravenous Immunoglobulin market has been segmented on the basis of type which comprise Plaque psoriasis, Scalp psoriasis, Nail psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis, Erythrodermic psoriasis and others. Plaque psoriasis is most common type and about 80% of the cases are plaque psoriasis.
On the basis of ivig treatment type it segmented into Topical corticosteroids, Vitamin D analogues (Calcipotriene, Calcitriol), Anthralin, Topical retinoids (Retinol, Tretinoin (retinoic acid / retin-A /Steiva-A), Adapalene (Differin), Tazarotene), Calcineurin (tacrolimus (Prograf), pimecrolimus (Elidel)), Salicylic acid, Coal tar, Moisturizers, and Others. Vitamin D analogs such as Calcipotriene and Calcitriol very helpful and helps to slow skin cell growth. Topical retinoids like are Retinol, Tretinoin (retinoic acid / retin-A /Steiva-A), Adapalene (Differin), Tazarotene are vitamin A derivatives that helps to reduce inflammation.
Regional Analysis
The North American region, heading with the presence of a large number of key players and a well-established healthcare sector accounts for the leading market in the global IVIg market.
The US market backed by the high expenditure on healthcare accounts for the largest contributor to the growth of the regional market. Moreover, the increasing prevalence of immunodeficiency disorder and rising demand for treatment measures provide impetus to market growth.
The intravenous immunoglobulin market in the European region accounts for the second-largest market, globally.
The IVIg market in Europe is fostered by the high per capita income and robust healthcare penetration in the region. The strong market growth in countries like Germany & France drives the regional market growth, large scale. Moreover, factors such as the increasing investments in healthcare and the rising number of patients with immune system diseases are helping the market to create a larger revenue pocket.
The Asia Pacific intravenous immunoglobulin market is expected to perceive an exponential growth. Factors such as the vast population and the burgeoning medical treatment market, especially in India & China, drive the growth of the regional market. Vietnam, Thailand, and Malaysia among the other South East Asian countries are projected to contribute significantly to the market growth in the region. With the growing Medical Tourism markets in India & Malaysia, the APAC region will register a significant CAGR during the review period.
Related Reports:
Lung cancer therapeutics Market
Vacuum blood collection tube Market
For More Information, Please Visit @ Market Research Future
Chinese
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek